Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kelly

Showing results (171-180 of 253) with videos related to

Pageof 26
Sort By:
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2023
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate CancerSusan F Slovin, Karen Knudsen, Susan Halabi, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
European Urology|August 18, 2019
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular ComorbiditiesGrace Lu-Yao, Nikita Nikita, Scott W Keith, et al.
The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.
Journal of Cellular and Molecular Medicine|July 9, 2009
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulationJennifer S Carew, Ernest C Medina, Juan A Esquivel, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 15, 2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerDarryl T Martin, Christopher J Hoimes, Hristos Z Kaimakliotis, et al.
Cancer|April 28, 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris, Oren Smaletz, David Solit, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumabAndrew B Nixon, Yingmiao Liu, Qian Yang, et al.
Pageof 26

Showing results (171-180 of 253) with videos related to

Sort By:
Pageof 26
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2023
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate CancerSusan F Slovin, Karen Knudsen, Susan Halabi, et al.
Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
European Urology|August 18, 2019
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular ComorbiditiesGrace Lu-Yao, Nikita Nikita, Scott W Keith, et al.
The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.
Journal of Cellular and Molecular Medicine|July 9, 2009
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulationJennifer S Carew, Ernest C Medina, Juan A Esquivel, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 15, 2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerDarryl T Martin, Christopher J Hoimes, Hristos Z Kaimakliotis, et al.
Cancer|April 28, 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinomaMichael J Morris, Oren Smaletz, David Solit, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumabAndrew B Nixon, Yingmiao Liu, Qian Yang, et al.
Pageof 26